Switch to:
More From Other Websites
Why Pfizer's buyback may be bad medicine for the stock Oct 24 2014
Ex-Bank of New York Mellon employee pleads guilty to insider trading Oct 24 2014
Ex-Bank of New York Mellon trader pleads guilty to insider trading Oct 24 2014
Bristol-Myers Beats Q3 Views As Eliquis Revives Oct 24 2014
Bristol-Myers Beats on Q3 Earnings, Maintains Guidance Oct 24 2014
Pfizer (PFE) $11 Billion Stock Repurchase Plan May End AstraZeneca (AZN) Bid Oct 24 2014
AstraZeneca cancer drug pipeline gets boost from European green light Oct 24 2014
Lynparza™ (olaparib) receives positive CHMP opinion in the EU for the maintenance treatment of... Oct 24 2014
AstraZeneca ovarian cancer drug wins European green light Oct 24 2014
Weaker travel and leisure stocks push FTSE lower Oct 24 2014
Pfizer's $11 bln buyback plan deflates AstraZeneca bid hopes Oct 24 2014
Europe opens lower; Ebola case in New York weighs Oct 24 2014
Pfizer board authorizes $11 billion share repurchase Oct 23 2014
Novartis' Secukinumab Receives Favorable FDA Panel Vote Oct 23 2014
Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of... Oct 23 2014
Market report: Smith & Nephew rises on deal talk Oct 22 2014
Markets open for trading: AbbVie/Shire deal scrapped Oct 21 2014
Will GlaxoSmithKline (GSK) Earnings Suffer on China Probe? Oct 20 2014
The shares tipped to fall if Labour wins next year’s general election Oct 20 2014
BUZZ-European healthcare: safety check Oct 20 2014


Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK